New abortive agents for the treatment of migraine.
Potrebic
S
S
Departments of Neurology and Anesthesiology, University of California, San Francisco, USA.
Raskin
N H
NH
D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D008881:Migraine Disorders / Q000175:diagnosis / Q000188:drug therapy*; D023303:Oxazolidinones / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011379:Prognosis; D012008:Recurrence; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D012720:Severity of Illness Index; D018170:Sumatriptan / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use; D014363:Tryptamines
D007211:Indoles; D023303:Oxazolidinones; D010880:Piperidines; D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C089750:zolmitriptan; C093622:rizatriptan; D018170:Sumatriptan; C106783:naratriptan